1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. Company
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
Delayed Hong Kong Stock Exchange  -  05/17 04:08:55 am EDT
8.720 HKD   +2.83%
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunotherapy
MT
03/29SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 67,787,426 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2021.
CI
03/25SciClone Pharma's Per-Share Earnings Slip in 2021
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.

Number of employees : 890 people.
Sales per Business
20202021Delta
Pharmaceuticals2 155.88100%3 035.29100% +40.79%
HKD in Million
Sales per region
20202021Delta
China2 061.0395.6%2 967.2197.8% +43.97%
Others94.844.4%68.082.2% -28.22%
HKD in Million
Managers
Name Title Age Since
Hong Zhao President, CEO & Executive Director 57 2020
Rongrong Pan Joint Secretary 42 -
Sin Man Chan Joint Secretary 34 -
Chih Wen Shao Vice President 58 -
Ming Xiang Wu Vice President 55 -
Yan Song Chang Vice President 53 -
Min Jia Vice President 50 -
Lian Zong Wu Vice President 47 -
Xiao Ning Guo, Dr. Vice President 43 -
Members of the board
Name Title Age Since
Zhen Fu Li Chairman 57 2020
Ping Chen, Dr. Independent Non-Executive Director 62 -
Wendy Hayes Independent Non-Executive Director 51 2021
Guo En Liu, Dr. Independent Non-Executive Director 64 -
Yushao Gu Independent Non-Executive Director 52 -
Hong Zhao President, CEO & Executive Director 57 2020
Daniel Lucius Vasella, Dr. Non-Executive Director 67 2020
Jesper Brandgaard Non-Executive Director 58 2020
Cen Shi Non-Executive Officer 45 2020
Quan Li Non-Executive Director 41 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 695,524,226 387,174,693 55.7% 10,189,963 1.5% 55.7%
Shareholders
NameEquities%
GL Capital Group 195,104,060 28.5%
CDH Investments Management (Hong Kong) Ltd. 106,536,790 15.5%
Ascendent Capital Partners (China) Ltd. 103,497,710 15.1%
Bank of China Limited 84,523,130 12.3%
Wei Hang Zhu 53,473,820 7.80%
Shanghai Pharmaceuticals Holding Co., Ltd 12,368,500 1.80%
Bosera Capital Management Co. Ltd. 12,368,500 1.80%
Hong Zhao 12,179,690 1.78%
Juli Information Consulting (Beijing) Co. Ltd. 11,979,690 1.75%
China Post & Capital Global Asset Management Ltd. 8,245,500 1.20%
Brand Portfolio
In partnership withAllbrands.markets
More brands of SciClone Pharmaceuticals (Holdings) Limited